Zydus Lifesciences Ltd. (ZYDUSLIFE): Zydus Lifesciences Share Price rises 2.32% as stock closes at Rs 1,130.60
- September 17, 2026
- Posted by: Harsh Piplani
- Category: News
Zydus Lifesciences Share Price rose 2.32% to Rs 1,130.60 today. The company’s market capitalisation stands at Rs 1,09,625.67 crore. The supplied data confirms the price rise, while a company-specific catalyst is not established.
Zydus Lifesciences Share Price is in focus today after the stock rose 2.32% to Rs 1,130.60 from the previous close of Rs 1,105. The move lifted the company’s market capitalisation to Rs 1,09,625.67 crore and placed Zydus Lifesciences Ltd. among the notable Stocks in News in the Indian stock market. The day’s action is relevant because the supplied data confirms a clear share price gain, yet it does not establish a company-specific catalyst. For readers tracking Zydus Lifesciences Share Price Today, Univest shows the event through the live market update, and the same data helps frame the stock’s valuation, sector position and peer context without speculation.
The stock opened at Rs 1,102.40, touched an intraday high of Rs 1,134.35 and a low of Rs 1,101.55. Turnover stood at Rs 1.01 crore. In stock news terms, the focus is on what the numbers show: a positive daily move, a trading range that stayed close to the open, and a valuation profile that can be read alongside Healthcare peers. Univest presents this as a factual Zydus Lifesciences Share Price update rather than a story built around an unverified trigger.
Zydus Lifesciences Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,130.6 |
| Previous Close | Rs 1,105 |
| Today's Move | Rs 25.6 (+2.32%) |
| Open | Rs 1,102.4 |
| High | Rs 1,134.35 |
| Low | Rs 1,101.55 |
| Turnover | Rs 1.01 crore |
| Market Capitalisation | Rs 1,09,625.67 crore |
| Market Cap Category | Large Cap |
Zydus Lifesciences Ltd. (ZYDUSLIFE) rose to Rs 1,130.6 from the previous close of Rs 1,105, a move of Rs 25.6 or 2.32%. The stock opened at Rs 1,102.4, reached a high of Rs 1,134.35, recorded a low of Rs 1,101.55.
Zydus Lifesciences Share Price Today reflects a Rs 25.60 rise over the previous close, with the stock ending at Rs 1,130.60 after opening at Rs 1,102.40. The day’s high of Rs 1,134.35 remained close to the closing level, while the low of Rs 1,101.55 stayed near the open. Turnover of Rs 1.01 crore provides a factual traded-value measure for the session. The supplied data confirms the price rise and the day’s range, but it does not establish a company-specific reason for the move. For Zydus Lifesciences Stock News readers, the most useful interpretation is simply that the stock finished higher on the day and stayed within a relatively contained intraday band.
Zydus Lifesciences Ltd. (ZYDUSLIFE) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,09,625.67 crore |
| P/E Ratio | 24.42x |
| P/B Ratio | 4.09x |
| ROE | 19.69% |
| ROCE | 21.39% |
| EPS | Rs 45.24 |
| Book Value Per Share | Rs 270.31 |
| Dividend Yield | 0.09% |
Zydus Lifesciences Ltd. (ZYDUSLIFE) fundamental metrics show P/E 24.42x, P/B 4.09x, ROE 19.69%, ROCE 21.39%. These figures provide context only and are not a buy or sell signal.
Zydus Lifesciences Ltd. has a market capitalisation of Rs 109625.67 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 24.42x, P/B at 4.09x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 19.69% and ROCE of 21.39%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 45.24, book value per share of Rs 270.31, dividend yield of 0.09%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.35x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 24.42x |
| Benchmark Median P/E | 31.35x |
| Benchmark Average P/E | 47.81x |
| Benchmark P/E Range | 3.45x to 661.74x |
| Company P/B Ratio | 4.09x |
| Benchmark Median P/B | 2.98x |
| Company ROE | 19.69% |
| Benchmark Median ROE | 11.78% |
| Company ROCE | 21.39% |
| Benchmark Median ROCE | 13.65% |
| Company Market Capitalisation | Rs 1,09,625.67 crore |
| Benchmark Median Market Cap | Rs 735.67 crore |
Zydus Lifesciences Ltd. (ZYDUSLIFE) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Zydus Lifesciences Ltd. (ZYDUSLIFE) has a P/E ratio of 24.42x, which is below the benchmark median of 31.35x, a difference of -22.11%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Zydus Lifesciences Ltd. (ZYDUSLIFE) has a ROE of 19.69%, which is above the benchmark median of 11.78%, a difference of +67.15%. Zydus Lifesciences Ltd. (ZYDUSLIFE) has a ROCE of 21.39%, which is above the benchmark median of 13.65%, a difference of +56.7%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,40,277.97 | 36.77 | 5.14 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,43,965.63 | 83.5 | 13.83 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,84,478.41 | 84.11 | 20.44 | 26.76 | 19.27 |
| Cipla Ltd. | CIPLA | 1,09,949.53 | 32.59 | 3.12 | 11.83 | 16 |
| Laurus Labs Ltd. | LAURUSLABS | 1,03,902.04 | 94.19 | 18.26 | 18.31 | 18.2 |
Zydus Lifesciences Ltd. (ZYDUSLIFE) has a P/E ratio of 24.42x compared with the displayed peer median of 83.5x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 19.69% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 21.39% versus the displayed peer median of 19.11%, providing a capital-efficiency comparison. Zydus Lifesciences Ltd. (ZYDUSLIFE) has a market capitalisation of Rs 1,09,625.67 crore. Among the 5 peers shown, 4 have a larger market capitalisation.
Why Investors Are Watching Zydus Lifesciences
- The stock rose 2.32% today and closed at Rs 1,130.60.
- The day’s high was Rs 1,134.35 and the low was Rs 1,101.55.
- Market capitalisation stands at Rs 1,09,625.67 crore.
- P/E is 24.42, below the industry median of 31.35 and average of 47.81.
- ROE is 19.69% and ROCE is 21.39%, both above the same-industry median.
About Zydus Lifesciences
Zydus Lifesciences Ltd. is part of the Pharmaceuticals & Drugs industry in the Healthcare sector. The company’s market presence is reflected in its Rs 1,09,625.67 crore market capitalisation, and its financial profile shows EPS of Rs 45.24, book value of Rs 270.31 and dividend yield of 0.09%. These figures indicate a business that is being followed for both earnings and asset-backed context.
For investors reading Zydus Lifesciences Stock News, the company’s relevance comes from its scale within Indian pharmaceuticals, its return ratios and how its valuation compares with listed peers. Zydus Lifesciences Share News often gets attention because the stock combines a sizeable market cap with sector-specific benchmarking that can be followed on Univest alongside broader Healthcare updates. The company’s current price move adds a fresh event layer to that longer-term business profile.
Track Zydus Lifesciences Share Price on Univest
Use Zydus Lifesciences Ltd. (ZYDUSLIFE) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Zydus Lifesciences Share Price rising today?
Ans. The supplied data confirms a 2.32% rise in Zydus Lifesciences Share Price to Rs 1,130.60, but it does not establish a company-specific catalyst. The move is therefore best read as a verified same-day price event.
What is Zydus Lifesciences Share Price today?
Ans. Zydus Lifesciences Share Price today is Rs 1,130.60. It was up Rs 25.60, or 2.32%, from the previous close of Rs 1,105, making it a notable stock news event for the session.
What is the market capitalisation of Zydus Lifesciences?
Ans. Zydus Lifesciences has a market capitalisation of Rs 1,09,625.67 crore. That places the company well above the same-industry median market cap of Rs 735.67 crore in the supplied benchmark set.
How are Zydus Lifesciences valuation ratios reading?
Ans. Zydus Lifesciences trades at a P/E of 24.42 and a P/B of 4.09. Its P/E is below the industry median, while its P/B is slightly above the benchmark median. The company trades at a P/E ratio of 24.42x.
What do Zydus Lifesciences earnings and book value show?
Ans. EPS is Rs 45.24 and book value is Rs 270.31 per share. EPS shows earnings attributable to each share, while book value reflects the accounting net worth behind each share at the current stage.
How do Zydus Lifesciences ROE and ROCE compare with peers?
Ans. Zydus Lifesciences reports ROE of 19.69% and ROCE of 21.39%. Both are above the same-industry median, and ROCE also compares well against several large pharmaceutical peers in the supplied set.
How does Zydus Lifesciences Share Price compare with peers on valuation?
Ans. On P/E, Zydus Lifesciences is lower than Sun Pharma, Divi's Laboratories, Torrent Pharmaceuticals, Cipla and Laurus Labs. That makes the stock relatively lower-valued on earnings among the peers listed here.
